Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0000054

Alprostadil

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Prostaglandin E1, (11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid, Alprostadil, PGE1

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H34O5
Numéro CAS:
745-65-3
Poids moléculaire :
354.48
Numéro Beilstein :
5294062
Numéro CE :
212-017-2
Numéro MDL:
MFCD00077860
Code UNSPSC :
41116107
ID de substance PubChem :
329830830
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

alprostadil

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

−20°C

Chaîne SMILES 

O=C1[C@H](CCCCCCC(O)=O)[C@@H](/C=C/[C@H](CCCCC)O)[C@H](O)C1

InChI

1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1

Clé InChI

GMVPRGQOIOIIMI-DWKJAMRDSA-N

Informations sur le gène

human ... PTGER1(5731) , PTGER2(5732)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Alprostadil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301

Conseils de prudence

P301 + P310 + P330

Classification des risques

Acute Tox. 3 Oral

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 5

1 of 5

Prostaglandin A1 synthetic

Sigma-Aldrich

P7265

Prostaglandin A1

Prostaglandin E2 synthetic, powder, BioReagent, suitable for cell culture

Sigma-Aldrich

P0409

Prostaglandin E2

vibrant-m

H0200000

Heparin sodium

Acétate d’ammonium BioXtra, ≥98%

Sigma-Aldrich

A7330

Acétate d′ammonium

Sodium Dodecyl Sulfate BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)

Sigma-Aldrich

L3771

Sodium Dodecyl Sulfate

Takashi Onoe et al.
Transplantation, 95(12), 1521-1527 (2013-04-20)
Small-for-size syndrome remains the greatest limiting factor of expanding segmental liver transplantation from living donors. Portal hyperperfusion is considered to substantially contribute to small-for-size syndrome. We investigated the impact of continuous portal infusion of prostaglandin E1 (PGE1) on small-for-size grafts
Pierre Costa et al.
Drugs, 72(17), 2243-2254 (2012-11-23)
The global burden of erectile dysfunction (ED) is increasing. It is estimated that 8-19% of men in Europe have ED and that by 2025 the prevalence of ED worldwide will reach 322 million. The gold standard therapy for ED is
K Schrör et al.
VASA. Zeitschrift fur Gefasskrankheiten, 33(3), 119-124 (2004-10-06)
The mechanisms of anti-ischemic effects of PGE1 in patients with peripheral arterial occlusive disease (PAD) are probably complex and clearly not limited to a direct vasodilator action. In addition to the known effects on blood flow, viscosity, fibrinolysis and platelet
Kristine J Guleserian et al.
The Journal of thoracic and cardiovascular surgery, 145(1), 206-213 (2012-12-19)
Bilateral pulmonary artery banding with or without ductal stenting has been performed as a resuscitative intervention for patients considered at too high risk for conventional single ventricle palliation. The purpose of the present study was to determine the outcomes using
Lisbeth Svensson et al.
Infection and immunity, 82(10), 4307-4314 (2014-07-30)
Platelet activation and aggregation have been reported to occur in response to a number of Gram-positive pathogens. Here, we show that platelet aggregates induced by Streptococcus pyogenes were unstable and that viable bacteria escaped from the aggregates over time. This
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique